Welcome to our dedicated page for Axogen news (Ticker: AXGN), a resource for investors and traders seeking the latest updates and insights on Axogen stock.
Axogen, Inc. (NASDAQ: AXGN) is a leading medical products company specializing in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration. The company's core mission is to restore peripheral nerve function and improve the quality of life for patients suffering from traumatic injuries or surgical procedures that impact nerve function and sensation.
Axogen's innovative product portfolio includes:
- Avance® Nerve Graft: The first and only commercially available allograft for bridging nerve discontinuities.
- Axoguard® Nerve Connector: A coaptation aid designed for the close approximation of severed nerves.
- Axoguard® Nerve Protector: A product that shields nerves during the healing process.
- Axoguard® Nerve Cap: A surgical implant to isolate and protect a peripheral nerve end, minimizing painful neuroma development.
- Axoguard HA+ Nerve Protector: A next-gen nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries.
- Avive® Soft Tissue Membrane: A biologically active product aiding in nerve healing.
- Axotouch® Two-Point Discriminator: An assessment tool for measuring the innervation density of skin surface areas.
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries. The company continues to expand its global presence and partnerships, ensuring that healthcare providers and surgeons have access to clinically and economically effective nerve repair solutions.
Recent achievements include the launch of the Axoguard HA+ Nerve Protector, which provides enhanced nerve gliding and protection for a wide range of peripheral nerve injuries. The company reported strong performance in Q4 2023, with an expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
For more information, visit www.axogeninc.com.
Rhea-AI Summary
Axogen, a global leader in surgical solutions for peripheral nerve injuries, announced the retirement of President and CEO Karen Zaderej by January 2025. The Board will search for her successor and Ms. Zaderej will continue as a consultant for nine months. The company reported 2023 revenue of $158.8 million, with 15% year-over-year growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
-
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) announces the promotions of three research and development team members and the departure of Angelo Scopelianos, Ph.D. The promotions include Erick DeVinney to Chief Innovation Officer, Ivica Ducic, M.D., Ph.D., to Chief Medical Officer, and Stacy Arnold to Vice President of Product Development and Clinical Research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.67%
Tags
-
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) appoints Kathy Weiler, a senior executive with 20+ years of experience, to its Board of Directors. Weiler brings her extensive commercial experience to support Axogen's patient activation and commercial execution as the company drives toward being cash flow positive.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.1%
Tags
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) appoints Nir Naor as CFO, replacing Peter Mariani. Naor brings over 20 years of experience in life sciences finance. The move aligns with the company's focus on revenue growth and profitability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) announced the induction of Harold D. Tamayo as Vice President of Finance and Investor Relations. Mr. Tamayo brings over 20 years of experience in healthcare and life sciences. He has held leadership roles in companies such as McKesson, Merck, Novartis, and CVS Health. As part of his employment, Mr. Tamayo was awarded an equity grant, including non-qualified stock options to purchase 65,800 shares and non-qualified restricted stock units representing 37,500 shares of the Company’s common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.92%
Tags
-
Rhea-AI Summary
Axogen, Inc. (NASDAQ: AXGN) to present at Piper Sandler 35th Annual Healthcare Conference on November 30, 2023. Karen Zaderej, Chairman, CEO, and President, will speak about innovative surgical solutions for peripheral nerve injuries. The webcast can be accessed live on the Investors page at www.axogeninc.com and will be available for replay for 90 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
Rhea-AI Summary
Axogen, Inc. reported a 12% increase in revenue for the third quarter of 2023, reaching $41.3 million. The company also experienced a gross margin of 80.5% and an adjusted net income of $0.7 million. The balance of all cash and cash equivalents and investments on September 30, 2023, was $38.6 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
36.9%
Tags
-
Rhea-AI Summary
Axogen, Inc. to report third quarter 2023 financial results on November 7, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
-
Rhea-AI Summary
Axogen, Inc. announces full launch of Axoguard HA+ Nerve Protector, expanding opportunities for surgeons to treat nerve protection challenges.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
Rhea-AI Summary
Axogen, Inc. announced CEO Karen Zaderej's participation in two investor conferences in September.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.03%
Tags
FAQ
What is the current stock price of Axogen (AXGN)?
The current stock price of Axogen (AXGN) is $13.34 as of November 22, 2024.
What is the market cap of Axogen (AXGN)?
The market cap of Axogen (AXGN) is approximately 588.0M.
What is Axogen, Inc. focused on?
Axogen, Inc. specializes in the science, development, and commercialization of technologies for peripheral nerve repair and regeneration.
What are some key products offered by Axogen?
Key products include Avance® Nerve Graft, Axoguard® Nerve Connector, Axoguard® Nerve Protector, Axoguard® Nerve Cap, and Avive® Soft Tissue Membrane.
In which markets are Axogen's products available?
Axogen's products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.
What recent product did Axogen launch?
Axogen recently launched the Axoguard HA+ Nerve Protector, a next-generation nerve protection device designed to enhance nerve gliding and provide long-term protection.
What is the Avance® Nerve Graft?
The Avance® Nerve Graft is a commercially available allograft for bridging nerve discontinuities, providing a biologically active solution for nerve repair.
How did Axogen perform financially in Q4 2023?
Axogen reported strong performance with expected annual revenue growth of 11% to 14% and anticipated gross margins between 76% and 79%.
What does the Axoguard® Nerve Cap do?
The Axoguard® Nerve Cap is a surgical implant that isolates and protects a peripheral nerve end, helping reduce the development of painful neuromas.
What is the function of the Axotouch® Two-Point Discriminator?
The Axotouch® Two-Point Discriminator is used to measure the innervation density of any surface area of the skin.
Who is the current CEO of Axogen?
The current CEO, Chairman, and President of Axogen, Inc. is Karen Zaderej.
Where can I find more information about Axogen?
For more information, visit Axogen's official website at www.axogeninc.com.
Axogen, Inc.
Nasdaq:AXGN
AXGN Rankings
AXGN Stock Data
587.95M
41.56M
5.55%
84.61%
2.57%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
United States of America
ALACHUA